Nemtabrutinib for Chronic Lymphocytic Leukemia

This trial tests a new drug called nemtabrutinib, a type of targeted therapy, for individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) that hasn't responded to other treatments. These conditions cause an excess of malfunctioning white blood cells, increasing vulnerability to infections. The trial aims to determine if nemtabrutinib can control the disease when other drugs fail. Individuals who have tried other treatments and still have active CLL/SLL might be suitable for this trial. Participants will take a daily pill and attend regular clinic visits for monitoring. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering participants a chance to potentially benefit from a new therapy.

You may need to stop certain medications before joining the trial. Specifically, if you are taking drugs that are P-gp substrates with a narrow therapeutic index, CYP3A strong inducers, or CYP3A strong inhibitors, a washout period (time without taking these medications) of at least 5 times the half-life is required. Additionally, you cannot be on systemic anti-CLL therapy, certain radiotherapies, or warfarin close to the start of the trial.

Research has shown that nemtabrutinib has a safety profile that most participants can handle, with generally mild and manageable side effects. For instance, studies found that different doses, including 65 mg, were well-tolerated by patients. This suggests that while some side effects may occur, they are usually not severe. Participants in a trial work closely with doctors to monitor and manage any side effects effectively.¹²³⁴⁵

Unlike the standard treatments for chronic lymphocytic leukemia (CLL), which often include medications like ibrutinib or venetoclax, nemtabrutinib offers a novel approach by targeting Bruton’s tyrosine kinase (BTK) in a different way. Most CLL treatments work by blocking this enzyme to prevent cancer cell growth, but nemtabrutinib has a unique binding mechanism that may overcome resistance seen with other BTK inhibitors. Researchers are excited about this treatment because it could be effective for patients who have stopped responding to existing therapies, offering a new hope in managing CLL more effectively.

Research has shown that nemtabrutinib, the investigational treatment in this trial, may effectively treat chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). One study found that about 75% of patients with CLL responded positively to nemtabrutinib, including those with specific genetic mutations. Another study demonstrated that combining nemtabrutinib with venetoclax led to positive responses in all patients with relapsed or hard-to-treat CLL. These findings suggest that nemtabrutinib could be effective even in challenging cases, offering promising new treatment options for people with CLL/SLL.¹²⁴⁶⁷